Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?
Moderna stock took a beating in January after the company slashed its outlook for 2024 and 2025 and missed the mark in a CMV study.
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
Moderna stock took a beating in January after the company slashed its outlook for 2024 and 2025 and missed the mark in a CMV study.